Qiagen (QGEN) reported $532.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.1%. EPS of $0.61 for the same period compares to $0.59 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $525.99 million, representing a surprise of +1.25%. The company delivered an EPS surprise of +5.17%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

核心观点 - 华尔街分析师预测Qiagen(QGEN)即将公布的季度每股收益为0.5美元 同比增长6.4% 预计营收达4.6404亿美元 同比增长1.1% [1] - 过去30天内分析师对Qiagen的每股收益共识预估未作修正 显示市场预期保持稳定 [2] - 分析师对特定产品线的销售预测显示差异化表现 其中QIAstat-Dx诊断解决方案预计达3015万美元(+20.6%) QuantiFERON诊断解决方案预计达1.1116亿美元(+10.1%) [5] 财务预测 - 分子诊断业务收入预计达2.5258亿美元(+3.5%) 生命科学业务收入预计达2.1117亿美元(-1.8%) [8][9] - 样本技术产品线销售预计达1.5054亿美元(-2.9%) 诊断解决方案整体预计达1.8035亿美元(+6.1%) [6] - NeuMoDx诊断解决方案预计仅460万美元(-48.9%) 基因组学/NGS产品线预计5460万美元(-0.7%) [7] 产品线表现 - PCR/核酸扩增产品线预计6764万美元(-0.5%) 其他产品组合预计1095万美元(-0.5%) [8] - 诊断解决方案中的其他产品预计3445万美元(-1.6%) [9] - 公司股价过去一月上涨6.2% 同期标普500指数上涨11.5% [9]